Press releases
Browse Canadian-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
-
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada
-
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
-
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
-
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
-
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults
-
VOLUNTARILY RECALL OF TUMS EXTRA STRENGTH (750MG) ASSORTED BERRY 100CT AND ROLL 3X8CT
VOLUNTARILY RECALL OF TUMS EXTRA STRENGTH (750MG) ASSORTED BERRY 100CT AND ROLL 3X8CT
-
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
-
Important information on Advil Cold & Sinus Daytime / Nighttime Convenience Pack
Important information on Advil Cold & Sinus Daytime / Nighttime Convenience Pack
-
Changing attitudes to vaccination post-COVID suggest investing in our own health is a key priority for many Canadians
Changing attitudes to vaccination post-COVID suggest investing in our own health is a key priority for many Canadians
-
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
-
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and
-
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
-
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
-
GSK’s ZEJULA is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy
ZEJULA (niraparib) has received conditional positive recommendations for reimbursement
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
-
GSK named one of Canada’s Top 100 Employers in the year of the pandemic
GSK named one of Canada’s Top 100 Employers in the year of the pandemic
-
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
-
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
-
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
